Radosław Mądry

TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.

TL;DR: Data indicate that the median duration of progression-free survival (PFS) is significantly longer for the niraparib group than for the placebo group regardless of the presence or absence of gBRCA mutations or HRD status.

TL;DR: Women undergoing chemotherapy for ovarian cancer change their dietary habits in a pro healthy direction, and these changes are more expressed in patients undergoing subsequent-line chemotherapy.